Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.71 -0.09 (-0.39%) 6:44 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.71 -0.09 (-0.39%) 6:44 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Zacks News
Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance
by Zacks Equity Research
Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
by Zacks Equity Research
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
by Zacks Equity Research
Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.
Hims & Hers Health, Inc. (HIMS) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.15, marking no change from the previous day.
Abbott's (ABT) EPD Expansion Continues Despite FX Headwind
by Zacks Equity Research
Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
by Zacks Equity Research
Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.
Alcon (ALC) Achieves FDA 510(k) Clearance for Unity VCS and Unity CS
by Zacks Equity Research
Alcon (ALC) gets FDA 510(k) clearance for its Unity VCS and Unity CS. The company will start a thorough program to get real-world feedback before the systems' commercial launch in 2025.
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
by Zacks Equity Research
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
by Zacks Equity Research
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
by Zacks Equity Research
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
by Zacks Equity Research
Thermo Fisher (TMO) announces a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices lab in Middleton, WI
Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Haemonetics (HAE) Expands VASCADE Line With New Limited Launch
by Zacks Equity Research
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology
by Zacks Equity Research
This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
by Zacks Equity Research
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
by Zacks Equity Research
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $24.15, indicating a +1.68% shift from the previous trading day.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
by Zacks Equity Research
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.